A phase II study of combined ridaforolimus and dalotuzumab compared with exemestane in patients with estrogen receptor-positive breast cancer
José Baselga(Novartis (Switzerland)), Hope S. Rugo(City of Hope), David Mauro(Merck & Co., Inc., Rahway, NJ, USA (United States)), Ahmad Awada(Centre Hospitalier Interrégional Edith Cavell), Beverly Moy(Global Cancer Institute), Antoinette R. Tan(Wake Forest University), Kathryn J. Ruddy(Mayo Clinic in Arizona), Marianne Ewertz(Odense University Hospital), Tufia C. Haddad(Mayo Clinic), Peter Vuylsteke(Champalimaud Foundation), Joanne L. Blum(Texas Oncology), Christine K. Gause(Merck & Co., Inc., Rahway, NJ, USA (United States)), Javier Cortés(Villa Maria Hospital), Lamar Eaton(Merck & Co., Inc., Rahway, NJ, USA (United States)), Eva Ciruelos(Hospital Universitario 12 De Octubre), Serafín Morales(Hospital Universitari Arnau de Vilanova), Kumudu Pathiraja(Merck & Co., Inc., Rahway, NJ, USA (United States)), Mary Jones(Merck & Co., Inc., Rahway, NJ, USA (United States)), Ellie Im(Merck & Co., Inc., Rahway, NJ, USA (United States)), Scot Ebbinghaus(Merck & Co., Inc., Rahway, NJ, USA (United States))
Cited by 18
Related Papers
Pembrolizumab versus Ipilimumab in Advanced Melanoma
|New England Journal of Medicine|2015|5.9k
Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
|The Lancet|2014|4.7k
Tumor mutational load predicts survival after immunotherapy across multiple cancer types
|Nature Genetics|2019|4.4k
Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma
|New England Journal of Medicine|2013|3.4k
Pembrolizumab for Early Triple-Negative Breast Cancer
|New England Journal of Medicine|2020|3.1k